CASE STUDY | SAFETY AND EFFECTIVENESS MATTER

SAFETY AND EFFECTIVENESS MATTER

Client Success Story

the situation

The Situation

  • An ultra-rare, fatal childhood condition exists with no effective treatment
  • Condition affects 36 infants per year in the U.S.
the solution

The Solution

  • Regulatory and Quality Consulting consultants submit an Orphan Drug and Pre-IND/End of Phase 2 (EOP2) Briefing Document to FDA
  • Secure meeting with the FDA
the results

The Results

  • FDA approves small clinical trial (25 patients)
  • Orphan Designation granted
  • Improved chances of therapy development

FDA approves small clinical trial (25 patients)
Orphan Designation granted
Improved chances of therapy development

Results Matter.

Ask us how we can help you commercialize orphan therapies.

Contact Form

  • This field is for validation purposes and should be left unchanged.